StockNews.com initiated coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Free Report) in a research report released on Saturday morning. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Stock Performance
NASDAQ TTNP opened at $5.77 on Friday. Titan Pharmaceuticals has a 52 week low of $4.24 and a 52 week high of $14.80. The company has a 50-day moving average price of $5.84 and a two-hundred day moving average price of $6.49.
Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) last posted its earnings results on Thursday, August 15th. The specialty pharmaceutical company reported ($2.29) EPS for the quarter.
About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
See Also
- Five stocks we like better than Titan Pharmaceuticals
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Palo Alto Analysts Drive it to New Highs: 50% Upside Is Possible
- How Technical Indicators Can Help You Find Oversold Stocks
- Roblox’s Growth Beyond Kids: Stock Set for Major Moves
- Technology Stocks Explained: Here’s What to Know About Tech
- 5 Oversold Stocks to Buy Right Now
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
